Company profile
AMARIN CORP PLC\UK
NASDAQ:AMRNBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Icosapent ethyl | approved | — | 3 | approved |
| Medroxyprogesterone acetate | approved | — | 5 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01492361 | phase3 | completed | 2011-11-01 | 2018-05-01 | Amarin Pharma Inc. | A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin |
| NCT01047501 | phase3 | completed | 2009-12-01 | 2011-02-01 | Amarin Pharma Inc. | Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) |
| NCT01047683 | phase3 | completed | 2009-12-01 | 2010-10-01 | Amarin Pharma Inc. | Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL |
| NCT00146211 | phase3 | completed | 2005-09-01 | 2007-08-01 | Amarin Neuroscience Ltd | TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| ANDA 083242 | ANDA | AMARIN PHARMACEUTICALS INC | ||||
Loading… | ||||||
| NDA 202057 | NDA | AMARIN PHARMACEUTICALS IRELAND LTD | ||||
Loading… | ||||||